ApoE in Atherosclerosis: A Protein With Multiple Hats
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ApoE is a key constituent of plasma LNPs although the secreted apoprotein is undetectable in plasma.
“apolipoprotein E (ApoE) is a key constituent of plasma LNPs7, 8 although the secreted apoprotein is undetectable in plasma.9, 10”
From ApoE is Secreted as a Lipid Nanoparticle by Mammalian Cells: Implications for Alzheimer’s Disease Pathogenesis (2025) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 21
- Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
- Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest. 1998;101:1726 -1736.
- Breslow JL. Mouse models of atherosclerosis. Science. 1996;272: 685-688.
- Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, Shimada M, Yazaki Y. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E: accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest. 1992;90:2084 -2091.
- Nikoulin IR, Curtiss LK. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J Clin Invest. 1998;101:223-234.
- Desurmont C, Caillaud JM, Emmanuel F, Benoit P, Fruchart JC, Castro G, Branellec D, Heard JM, Duverger N. Complete atherosclerosis regression after human apoE gene transfer in apoE-deficient/nude mice. Arterioscler Thromb Vasc Biol. 2000;20:435-442.
- Boisvert WA, Spangenberg J, Curtiss LK. Treatment of severe hypercho- lesterolemia in apolipoprotein E-deficient mice by bone marrow trans- plantation. J Clin Invest. 1995;96:1118 -1124.
- Mensenkamp AR, Jong MC, Van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol PJ, Hofker MH, Van Dijk KW, Havekes LM, Kuipers F. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem. 1999;274: 35711-35718.
- Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hyper- cholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468 -472.
- Hasty AH, Linton MF, Swift LL, Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J Lipid Res. 1999;40:1529 -1538.
- Thorngate FE, Rudel LL, Walzem RL, Williams DL. Low levels of extrahepatic nonmacrophage apoE inhibit atherosclerosis without cor- recting hypercholesterolemia in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:1939 -1945.
- Hasty AH, Linton MF, Brandt SJ, Babaev VR, Gleaves LA, Fazio S. Retroviral gene therapy in apoE-deficient mice: apoE expression in the artery wall reduces early foam cell lesion formation. Circulation. 1999; 99:2571-2576.
- Shimano H, Ohsuga J, Shimada M, Namba Y, Gotoda T, Harada K, Katsuki M, Yazaki Y, Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest. 1995;95:469 -476.
- Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14:55-61.
- Boisvert WA, Black AS, Curtiss LK. ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of apoE-deficient mice trans- planted with apoE-expressing macrophages. Arterioscler Thromb Vasc Biol. 1999;19:525-530.
- Zhu YH, Bellosta S, Langer C, Bernini F, Pitas RE, Mahley RW, Assmann G, von Eckardstein A. Low-dose expression of a human apo- lipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci U S A. 1998;95:7585-7590.
- Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997;94:4642-4646.
- Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active con- stituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol. 1986;136:3716 -3723.
- Kelly ME, Clay MA, Mistry MJ, Hsieh-Li H-M, Harmony JAK. Apoli- poprotein E inhibition of proliferation of mitogen-activated T lym- phocytes: production of interleukin 2 with reduced biological activity. Cell Immunol. 1994;159:124 -139.
- Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J Clin Invest. 1997;99:2752-2761.
- Ishigami M, Swertfeger DK, Hui MS, Granholm NA, Hui DY. Apoli- poprotein E inhibition of vascular SMC proliferation but not the inhi- bition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2000;20:1020 -1026.
Cited by
Sorted by citations
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · see citing works
Olin-Lewis, K., Benton, J. L., Rutledge, J. C., Baskin, D. G., Wight, T. N., & Chait, A. (2002) · Circulation Research · doi:10.1161/01.res.0000024691.82864.f0 · Cited by 19 · see citing works
Hernandez Arriaza, R., Reil, D., Fatuzzo, N., Fu, M., Dai, Y., Fernandez Martinez, D., Jiang, H., Holtzman, D. M., Greicius, M. D., & Khosla, C. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00503 · Cited by 2 · see citing works
- Authors
- Curtiss, L. K.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Curtiss, Linda K.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2000-08
- Volume
- 20
- Issue
- 8
- Pages
- 1852-1853
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2106591147
- Cited by
- 55
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 1 · 2022: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 3 · 2012: 1
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- apolipoprotein E, atherosclerosis
- MeSH terms
- Animals, Apolipoproteins E, Arteriosclerosis, Cholesterol, Humans, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
